Ajay Kirtane, M.D., SD, chief academic officer at Columbia University Medical Center/New York Presbyterian Hospital ...
The American College of Cardiology (ACC) 2013 Scientific Session Committee Chairman Miguel Quinones, M.D., explains some ...
DAIC Editor Dave Fornell explains his choices for the most innovative new technology on the expo floor at the American ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
The three-year results of a pivotal clinical study comparing the Edwards Sapien transcatheter heart valve and open-heart surgery demonstrated comparable outcomes. These new data from The PARTNER Trial were presented today as a late-breaking clinical trial at the American College of Cardiology's (ACC) 62nd Annual Scientific Session in San Francisco.
Spacelabs Healthcare has released the latest version of their cardiology information management system — Sentinel v.9 — with a new seamlessly integrated ABP module.
Terumo Interventional Systems expanded its family of Heartrail III Coronary Guiding Catheters to include a smaller profile 5 French Ikari shape, specifically designed to provide backup support and access to target coronary lesions during transradial catheterizations. The smaller 5 French Heartrail is designed to help physicians achieve access to the coronary arteries using a smaller-diameter catheter platform, and proprietary Ikari tip shapes, while providing the backup support and body of a traditionally larger French size catheter.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Alere Inc. announced the results of research presented at the American College of Cardiology’s 62nd Annual Scientific Session, which showed that a simple screening and management program can be effective in preventing heart failure for at-risk patients.
Results of the ULTIMA trial using endovascular therapy to treat submassive pulmonary embolism (PE) were presented at the American College of Cardiology 2013 meeting, The trial is the first randomized controlled trial comparing the use of an endovascular approach along with anticoagulation vs. anticoagulation therapy alone, the current standard of care.
Edwards Lifesciences Corporation announced that preliminary results from The PARTNER II Trial demonstrated similar one-year outcomes in mortality and major clinical events between the Edwards Sapien XT transcatheter aortic valve and the Edwards SAPIEN valve, yet fewer vascular events with the lower-profile Sapien XT valve. These data from The PARTNER II Trial studying transcatheter aortic valve replacement (TAVR) in inoperable patients with severe, symptomatic aortic stenosis were presented as a late-breaking clinical trial at the American College of Cardiology's (ACC) 62nd Annual Scientific Session in San Francisco.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Boston Scientific reports preliminary data in the PREVAIL clinical trial met two out of three co-primary endpoints. The data was supposed to be presented during the 2013 American College of Cardiology (ACC) meeting on March 9 as the lead-off late breaking trial. However, Boston Scientifc released information about the trial prior to ACC lifting the embargo. As a result of the embargo break, the presentation was pulled off the ACC agenda.
Medtronic Inc. announced it has received CE mark and will begin the European launch of the Attain Performa portfolio of quadripolar leads.
At the American College of Cardiology (ACC) conference, GE Healthcare unveiled DoseMap to alert interventional cardiologists to patient radiation exposure during longer procedures.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Accumetrics Inc. announced the presentation of a series of important data that solidifies the clinical utility of platelet reactivity testing. Real world outcomes data in high-risk patients receiving stents, a cost effectiveness analysis, and validation of a therapeutic window continue to demonstrate platelet reactivity as a critical element for improving the quality of care for the millions of patients on antiplatelet therapies worldwide.
AliveCor announced that its mobile Heart Monitor for iPhone is now available by prescription to enable patients to record their heart rhythm anytime, anywhere. The Heart Monitor, which makes home cardiac assessment quick and easy, is the first U.S. Food and Drug Administration (FDA)-cleared mobile device–based ECG monitor that is compatible with iPhone4 and 4S. The device was demonstrated at the ACC.13 annual meeting of the American College of Cardiology March 9 through March 11 in San Francisco.
Agfa HealthCare demonstrated its Impax CV Web+ solution at the American College of Cardiology's (ACC) 62nd Annual Scientific Session and Expo held in San Francisco from March 9-11. The technology transforms cardiovascular care delivery by providing physician access to cardiovascular images and reports regardless of location.